{"id":6697,"date":"2026-08-09T15:06:07","date_gmt":"2026-08-09T15:06:07","guid":{"rendered":"https:\/\/uksono.com\/home\/?page_id=6697"},"modified":"2026-08-09T15:07:07","modified_gmt":"2026-08-09T15:07:07","slug":"fatty-liver","status":"publish","type":"page","link":"https:\/\/uksono.com\/home\/fatty-liver\/","title":{"rendered":"Fatty Liver"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\r\n\r\n\r\n\r\n\r\n\r\nFatty Liver Disease (MASLD): Symptoms, Causes, Ultrasound, Fibrosis & Treatment | UKSONO Healthcare<\/title>\r\n\r\n<meta name=\"description\" content=\"Detailed guide to fatty liver disease (MASLD): causes, symptoms, liver blood tests, ultrasound findings, fat quantification, elastography, fibrosis, treatment and prognosis. Clinically reviewed by UKSONO Healthcare.\">\r\n\r\n<meta name=\"keywords\" content=\"fatty liver, MASLD, hepatic steatosis, fatty liver ultrasound, liver fibrosis, liver elastography, FibroScan, liver health check, fatty liver symptoms, fatty liver treatment, MASH, liver fat quantification, UKSONO Healthcare\">\r\n\r\n<meta name=\"robots\" content=\"index,follow,max-image-preview:large,max-snippet:-1\">\r\n<meta name=\"theme-color\" content=\"#10213a\">\r\n\r\n<link rel=\"canonical\" href=\"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/\">\r\n\r\n<meta property=\"og:type\" content=\"article\">\r\n<meta property=\"og:title\" content=\"Fatty Liver Disease (MASLD): Symptoms, Causes, Ultrasound & Treatment\">\r\n<meta property=\"og:description\" content=\"A detailed UKSONO guide to fatty liver disease, liver blood tests, ultrasound, elastography, fibrosis and treatment.\">\r\n<meta property=\"og:url\" content=\"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/\">\r\n<meta property=\"og:image\" content=\"https:\/\/uksono.com\/home\/wp-content\/uploads\/2024\/12\/Copy-of-Blue-and-White-Modern-Ultrasound-Clinic-Instagram-Post-900-x-471-mm.png\">\r\n<meta property=\"og:site_name\" content=\"UKSONO Healthcare\">\r\n\r\n<meta name=\"twitter:card\" content=\"summary_large_image\">\r\n<meta name=\"twitter:title\" content=\"Fatty Liver Disease (MASLD) | UKSONO Healthcare\">\r\n<meta name=\"twitter:description\" content=\"Symptoms, causes, blood tests, ultrasound, elastography, fibrosis, treatment and prognosis.\">\r\n\r\n<link rel=\"preconnect\" href=\"https:\/\/fonts.googleapis.com\">\r\n<link rel=\"preconnect\" href=\"https:\/\/fonts.gstatic.com\" crossorigin>\r\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=DM+Sans:wght@400;500;600;700&family=Manrope:wght@600;700;800&family=Playfair+Display:ital,wght@0,600;1,600&display=swap\" rel=\"stylesheet\">\r\n\r\n<script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"MedicalWebPage\", \"@id\": \"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/#webpage\", \"url\": \"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/\", \"name\": \"Fatty Liver Disease (MASLD): Symptoms, Causes, Ultrasound, Fibrosis & Treatment | UKSONO Healthcare\", \"headline\": \"Fatty Liver Disease (MASLD): Symptoms, Causes, Diagnosis, Ultrasound & Treatment\", \"description\": \"A detailed, clinically reviewed guide to metabolic dysfunction-associated steatotic liver disease (MASLD), including symptoms, causes, liver blood tests, ultrasound, liver fat quantification, elastography, fibrosis, treatment and prognosis.\", \"dateModified\": \"2026-08-08\", \"datePublished\": \"2026-08-08\", \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Christopher U. Agu MSc, PGDip, BSc\", \"jobTitle\": \"Clinical Lead \/ Consultant Sonographer\", \"affiliation\": {\"@type\": \"MedicalClinic\", \"name\": \"UKSONO Healthcare\"}}, \"publisher\": {\"@type\": \"MedicalClinic\", \"name\": \"UKSONO Healthcare\"}, \"about\": {\"@type\": \"MedicalCondition\", \"name\": \"Metabolic dysfunction-associated steatotic liver disease\"}, \"breadcrumb\": {\"@id\": \"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/#breadcrumb\"}}, {\"@type\": \"BreadcrumbList\", \"@id\": \"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/#breadcrumb\", \"itemListElement\": [{\"@type\": \"ListItem\", \"position\": 1, \"name\": \"Home\", \"item\": \"https:\/\/uksono.com\/home\/\"}, {\"@type\": \"ListItem\", \"position\": 2, \"name\": \"UKSONO Health Articles\", \"item\": \"https:\/\/uksono.com\/home\/health-articles\/\"}, {\"@type\": \"ListItem\", \"position\": 3, \"name\": \"Fatty Liver Disease (MASLD)\", \"item\": \"https:\/\/uksono.com\/home\/health-articles\/fatty-liver-disease-masld\/\"}]}, {\"@type\": \"FAQPage\", \"mainEntity\": [{\"@type\": \"Question\", \"name\": \"Can fatty liver be seen on ultrasound?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Ultrasound can detect moderate or marked hepatic steatosis and can assess the liver for structural changes, but mild steatosis may be less conspicuous and ultrasound alone cannot determine whether steatohepatitis is present.\"}}, {\"@type\": \"Question\", \"name\": \"Can you have fatty liver with normal liver blood tests?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Yes. Routine liver blood tests can be normal in people with fatty liver disease, so normal blood tests do not by themselves exclude MASLD or liver fibrosis.\"}}, {\"@type\": \"Question\", \"name\": \"Can fatty liver be reversed?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Liver fat and inflammation can improve substantially with sustained lifestyle and metabolic risk-factor changes, particularly weight loss where appropriate. Advanced fibrosis is more difficult to reverse, so early risk assessment is important.\"}}, {\"@type\": \"Question\", \"name\": \"What is the difference between fatty liver and liver fibrosis?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Fatty liver describes excess fat within liver cells. Fibrosis is scar tissue that develops after persistent liver injury. The amount of fibrosis is more closely related to long-term liver outcomes than the amount of fat alone.\"}}, {\"@type\": \"Question\", \"name\": \"What does elastography measure?\", \"acceptedAnswer\": {\"@type\": \"Answer\", \"text\": \"Elastography estimates liver stiffness. Higher stiffness can be associated with fibrosis, although inflammation, congestion, cholestasis and technical factors can also influence measurements.\"}}]}]}<\/script>\r\n\r\n<style>\r\n:root{\r\n --navy:#10213a;\r\n --navy2:#173f72;\r\n --blue:#3159c7;\r\n --blue2:#4f7cff;\r\n --gold:#b99755;\r\n --gold2:#e5cf94;\r\n --green:#0b7d45;\r\n --red:#b54132;\r\n --ink:#24364a;\r\n --muted:#647488;\r\n --line:#dbe5ef;\r\n --soft:#f5f8fc;\r\n --white:#fff;\r\n --max:1240px;\r\n --shadow:0 24px 70px rgba(16,33,58,.10);\r\n}\r\n*{box-sizing:border-box}\r\nhtml{scroll-behavior:smooth}\r\nbody{\r\n margin:0;\r\n color:var(--ink);\r\n background:#fff;\r\n font-family:\"DM Sans\",system-ui,-apple-system,\"Segoe UI\",Arial,sans-serif;\r\n font-size:17px;\r\n line-height:1.78;\r\n -webkit-font-smoothing:antialiased;\r\n}\r\na{color:#285b9e;text-decoration:none}\r\na:hover{text-decoration:underline}\r\nimg{max-width:100%;display:block}\r\n.shell{width:min(calc(100% - 30px),var(--max));margin:auto}\r\n\r\n\/* top *\/\r\n.article-top{\r\n position:sticky;top:0;z-index:100;\r\n border-bottom:1px solid rgba(16,33,58,.10);\r\n background:rgba(255,255,255,.96);\r\n backdrop-filter:blur(15px);\r\n}\r\n.article-top-inner{\r\n min-height:64px;\r\n display:flex;align-items:center;justify-content:space-between;gap:16px;\r\n}\r\n.article-brand{display:flex;align-items:center;gap:10px}\r\n.brand-mark{\r\n width:39px;height:39px;display:grid;place-items:center;border-radius:12px;\r\n background:linear-gradient(135deg,var(--navy),var(--blue));color:#fff;\r\n font:800 18px\/1 Manrope,sans-serif\r\n}\r\n.article-brand strong,.article-brand small{display:block}\r\n.article-brand strong{color:var(--navy);font:800 14px\/1.15 Manrope,sans-serif}\r\n.article-brand small{margin-top:2px;color:#8b713b;font-size:8px;font-weight:900;letter-spacing:.1em;text-transform:uppercase}\r\n.top-actions{display:flex;align-items:center;gap:8px}\r\n.top-btn{\r\n display:inline-flex;align-items:center;justify-content:center;min-height:40px;padding:0 13px;\r\n border:1px solid #d5e0eb;border-radius:999px;background:#fff;color:var(--navy);\r\n font-size:10px;font-weight:900\r\n}\r\n.top-btn.primary{border-color:transparent;background:linear-gradient(135deg,var(--navy),var(--blue));color:#fff}\r\n\r\n\/* breadcrumbs *\/\r\n.breadcrumbs{padding:14px 0;color:#7b8898;font-size:10px}\r\n.breadcrumbs a{color:#536a83}\r\n\r\n\/* hero *\/\r\n.hero{\r\n position:relative;overflow:hidden;\r\n background:\r\n radial-gradient(circle at 88% 10%,rgba(92,146,229,.33),transparent 28%),\r\n radial-gradient(circle at 9% 91%,rgba(185,151,85,.17),transparent 28%),\r\n linear-gradient(135deg,#071a31,#153e6a 66%,#2b6096);\r\n color:#fff;\r\n}\r\n.hero-grid{\r\n min-height:620px;\r\n display:grid;grid-template-columns:minmax(0,1fr) minmax(370px,.72fr);\r\n align-items:center;gap:48px;padding:clamp(54px,7vw,92px) 0;\r\n}\r\n.hero-kicker{\r\n display:inline-flex;align-items:center;gap:10px;color:#efd99f;\r\n font:900 10px\/1 Manrope,sans-serif;letter-spacing:.14em;text-transform:uppercase\r\n}\r\n.hero-kicker:before{content:\"\";width:32px;height:2px;background:linear-gradient(90deg,#fff,#d8ba72)}\r\n.hero h1{\r\n max-width:900px;margin:15px 0 18px;color:#fff;\r\n font:800 clamp(43px,5.8vw,76px)\/.99 Manrope,sans-serif;letter-spacing:-.06em\r\n}\r\n.hero h1 em{\r\n color:#f0d79a;font-family:\"Playfair Display\",Georgia,serif;font-weight:600\r\n}\r\n.hero-lead{max-width:830px;margin:0;color:#dfebf7;font-size:clamp(17px,1.4vw,20px);line-height:1.68}\r\n.hero-meta{display:flex;gap:8px;flex-wrap:wrap;margin-top:22px}\r\n.hero-meta span{\r\n padding:7px 9px;border:1px solid rgba(255,255,255,.18);border-radius:999px;\r\n background:rgba(255,255,255,.08);color:#e2ecf6;font-size:9px;font-weight:800\r\n}\r\n.hero-image{\r\n position:relative;overflow:hidden;height:470px;border-radius:28px;\r\n border:1px solid rgba(255,255,255,.20);box-shadow:0 30px 80px rgba(0,0,0,.23)\r\n}\r\n.hero-image img{width:100%;height:100%;object-fit:cover}\r\n.hero-image:after{content:\"\";position:absolute;inset:0;background:linear-gradient(180deg,transparent 50%,rgba(7,25,49,.65))}\r\n.hero-image-label{\r\n position:absolute;left:18px;right:18px;bottom:18px;z-index:2;padding:15px;border-radius:16px;\r\n background:rgba(7,25,49,.72);border:1px solid rgba(255,255,255,.18);backdrop-filter:blur(10px)\r\n}\r\n.hero-image-label strong,.hero-image-label span{display:block}\r\n.hero-image-label strong{font:800 15px\/1.2 Manrope,sans-serif}\r\n.hero-image-label span{margin-top:5px;color:#d3dfeb;font-size:10px}\r\n\r\n\/* quick facts *\/\r\n.quick-wrap{position:relative;z-index:10;margin-top:-34px}\r\n.quick-grid{\r\n display:grid;grid-template-columns:repeat(4,1fr);gap:10px;\r\n padding:14px;border:1px solid var(--line);border-radius:20px;background:#fff;box-shadow:var(--shadow)\r\n}\r\n.quick{\r\n padding:16px;border-radius:15px;background:linear-gradient(145deg,#f8fbff,#fff)\r\n}\r\n.quick small{display:block;color:#8b713b;font-size:8px;font-weight:900;letter-spacing:.09em;text-transform:uppercase}\r\n.quick strong{display:block;margin-top:5px;color:var(--navy);font:800 14px\/1.25 Manrope,sans-serif}\r\n.quick span{display:block;margin-top:5px;color:var(--muted);font-size:10px;line-height:1.45}\r\n\r\n\/* main layout *\/\r\n.article-layout{\r\n display:grid;grid-template-columns:245px minmax(0,1fr);gap:44px;\r\n padding:46px 0 88px;align-items:start\r\n}\r\n.toc{\r\n position:sticky;top:84px;padding:18px;border:1px solid var(--line);border-radius:18px;\r\n background:#f7faff;box-shadow:0 10px 28px rgba(16,33,58,.05)\r\n}\r\n.toc b{display:block;color:var(--navy);font:800 14px\/1.2 Manrope,sans-serif;margin-bottom:8px}\r\n.toc a{display:block;padding:7px 0;border-bottom:1px solid #e1e8ef;color:#566a80;font-size:11px;font-weight:700}\r\n.toc a:last-child{border-bottom:0}\r\n.toc a:hover{color:var(--blue);text-decoration:none}\r\n\r\n.article-content{min-width:0}\r\n.article-content section{scroll-margin-top:90px;padding:6px 0 33px;border-bottom:1px solid #e1e7ee}\r\n.article-content section:last-child{border-bottom:0}\r\n.article-content h2{\r\n margin:35px 0 13px;color:var(--navy);\r\n font:800 clamp(28px,3vw,38px)\/1.15 Manrope,sans-serif;letter-spacing:-.035em\r\n}\r\n.article-content h3{margin:27px 0 10px;color:var(--green);font:800 20px\/1.25 Manrope,sans-serif}\r\n.article-content h4{margin:22px 0 8px;color:#285b9e;font:800 16px\/1.3 Manrope,sans-serif}\r\n.article-content p{margin:0 0 16px;color:#40546a}\r\n.article-content li{margin-bottom:7px;color:#40546a}\r\n.article-content ul,.article-content ol{padding-left:23px}\r\n\r\n\/* callouts *\/\r\n.summary-box,.info-box,.warning-box,.clinical-box,.myth-box{\r\n margin:22px 0;padding:20px 21px;border-radius:17px;border:1px solid var(--line)\r\n}\r\n.summary-box{border-left:5px solid var(--blue2);background:linear-gradient(145deg,#f2f7ff,#fff)}\r\n.info-box{border-left:5px solid var(--green);background:#f2faf7}\r\n.warning-box{border-left:5px solid var(--red);background:#fff5f2;border-color:#efd5cf}\r\n.clinical-box{border-left:5px solid var(--gold);background:#fff9ed;border-color:#e8d8b4}\r\n.myth-box{border-left:5px solid #7c62b5;background:#f8f5ff}\r\n.summary-box strong,.info-box strong,.warning-box strong,.clinical-box strong,.myth-box strong{color:var(--navy)}\r\n.warning-box strong{color:#8f321f}\r\n\r\n\/* cards \/ tables *\/\r\n.two-col{display:grid;grid-template-columns:1fr 1fr;gap:14px;margin:20px 0}\r\n.card{\r\n padding:19px;border:1px solid var(--line);border-radius:17px;background:#fafcff\r\n}\r\n.card h3{margin-top:0}\r\n.table-wrap{overflow:auto;margin:22px 0;border:1px solid var(--line);border-radius:16px}\r\ntable{width:100%;border-collapse:collapse;min-width:680px}\r\nth{padding:13px;background:var(--navy);color:#fff;text-align:left;font-size:12px}\r\ntd{padding:13px;border-bottom:1px solid #e1e7ed;color:#40546a;font-size:13px;vertical-align:top}\r\ntr:nth-child(even) td{background:#f8fbff}\r\n\r\n\/* diagrams *\/\r\n.diagram{\r\n margin:26px 0;padding:22px;border:1px solid var(--line);border-radius:20px;background:#fbfdff;\r\n box-shadow:0 12px 34px rgba(16,33,58,.045)\r\n}\r\n.diagram-title{margin-bottom:15px;color:var(--navy);font:800 16px\/1.2 Manrope,sans-serif}\r\n.diagram-note{margin-top:11px;color:#788697;font-size:10px}\r\n.progression{display:grid;grid-template-columns:repeat(4,1fr);gap:9px}\r\n.stage{position:relative;padding:17px;border:1px solid #d9e3ed;border-radius:15px;background:#fff}\r\n.stage:not(:last-child):after{\r\n content:\"\u2192\";position:absolute;right:-12px;top:50%;transform:translateY(-50%);z-index:2;\r\n color:var(--gold);font-size:18px;font-weight:900\r\n}\r\n.stage b{display:block;color:var(--navy);font-size:13px}\r\n.stage span{display:block;margin-top:5px;color:#65758a;font-size:10px;line-height:1.4}\r\n.stage .stage-num{\r\n width:27px;height:27px;display:grid;place-items:center;margin-bottom:9px;border-radius:9px;\r\n background:linear-gradient(135deg,var(--navy),var(--blue));color:#fff;font-size:10px;font-weight:900\r\n}\r\n\r\n.weight-bars{display:grid;gap:11px}\r\n.weight-row{display:grid;grid-template-columns:100px 1fr 240px;gap:12px;align-items:center}\r\n.weight-label{color:var(--navy);font-weight:900;font-size:12px}\r\n.bar{height:15px;border-radius:999px;background:#eaf0f6;overflow:hidden}\r\n.bar i{display:block;height:100%;border-radius:999px;background:linear-gradient(90deg,var(--blue2),var(--green))}\r\n.weight-note{color:#607187;font-size:11px}\r\n\r\n\/* imaging comparison *\/\r\n.scan-compare{display:grid;grid-template-columns:1fr 1fr;gap:13px;margin:22px 0}\r\n.scan-panel{padding:20px;border:1px solid var(--line);border-radius:17px;background:#fff}\r\n.scan-panel.normal{background:linear-gradient(145deg,#f3faf7,#fff)}\r\n.scan-panel.fatty{background:linear-gradient(145deg,#fff9ec,#fff)}\r\n.scan-screen{\r\n height:180px;position:relative;overflow:hidden;margin-bottom:14px;border-radius:13px;\r\n background:linear-gradient(135deg,#0b0f14,#333a43)\r\n}\r\n.normal .scan-screen:before{\r\n content:\"\";position:absolute;inset:26px 30px;border-radius:45% 55% 48% 52%;\r\n background:radial-gradient(circle at 40% 40%,#777,#555 55%,#373737 75%);\r\n box-shadow:inset -25px -15px 40px rgba(0,0,0,.35)\r\n}\r\n.fatty .scan-screen:before{\r\n content:\"\";position:absolute;inset:26px 30px;border-radius:45% 55% 48% 52%;\r\n background:radial-gradient(circle at 40% 40%,#d6d6d6,#aaa 48%,#686868 73%,#343434);\r\n box-shadow:inset -25px -15px 40px rgba(0,0,0,.45)\r\n}\r\n.scan-screen:after{\r\n content:\"Illustrative ultrasound appearance\";position:absolute;left:12px;bottom:8px;\r\n color:#b9c4cf;font-size:8px;letter-spacing:.04em;text-transform:uppercase\r\n}\r\n.scan-panel b{display:block;color:var(--navy)}\r\n.scan-panel span{display:block;margin-top:5px;color:#67778a;font-size:11px;line-height:1.45}\r\n\r\n\/* reviewer *\/\r\n.reviewer{\r\n margin-top:38px;padding:24px;border:1px solid var(--line);border-radius:19px;\r\n background:linear-gradient(145deg,#fff,#f3f8ff 72%,#fff9ed)\r\n}\r\n.reviewer small{display:block;color:#8b713b;font-size:8px;font-weight:900;letter-spacing:.1em;text-transform:uppercase}\r\n.reviewer strong{display:block;margin-top:5px;color:var(--navy);font:800 20px\/1.2 Manrope,sans-serif}\r\n.reviewer span{display:block;margin-top:4px;color:#65758a;font-size:12px}\r\n.disclaimer{margin-top:13px;padding:17px;border:1px solid #eadbb8;border-radius:14px;background:#fff9ed;color:#6a5c42;font-size:12px}\r\n\r\n\/* booking *\/\r\n.booking{\r\n margin:32px 0;padding:31px;border-radius:22px;color:#fff;text-align:center;\r\n background:radial-gradient(circle at 88% 8%,rgba(79,124,255,.24),transparent 28%),linear-gradient(135deg,#071a31,#174675)\r\n}\r\n.booking h2{margin-top:0!important;color:#fff!important}\r\n.booking p{max-width:760px;margin:0 auto 16px;color:#dbe8f5!important}\r\n.booking a{\r\n display:inline-flex;align-items:center;justify-content:center;min-height:48px;padding:0 20px;\r\n border-radius:999px;background:linear-gradient(135deg,#0b7d45,#15955a);color:#fff;font-weight:900;font-size:12px\r\n}\r\n.booking a:hover{text-decoration:none}\r\n.booking small{display:block;margin-top:13px;color:#cbd8e5;font-size:10px}\r\n\r\n\/* faq *\/\r\n.faq details{padding:16px 0;border-top:1px solid #dfe6ee}\r\n.faq details:last-child{border-bottom:1px solid #dfe6ee}\r\n.faq summary{cursor:pointer;color:var(--navy);font-weight:900}\r\n.faq details p{margin-top:8px}\r\n\r\n\/* references *\/\r\n.references{font-size:14px}\r\n.references li{margin-bottom:9px}\r\n\r\n@media(max-width:1020px){\r\n .hero-grid{grid-template-columns:1fr}\r\n .hero-image{height:390px}\r\n .quick-grid{grid-template-columns:repeat(2,1fr)}\r\n .article-layout{grid-template-columns:1fr}\r\n .toc{position:relative;top:auto;display:flex;gap:7px;flex-wrap:wrap}\r\n .toc b{width:100%}\r\n .toc a{padding:7px 9px;border:1px solid #d9e3ee;border-radius:999px;background:#fff;font-size:10px}\r\n .progression{grid-template-columns:repeat(2,1fr)}\r\n .stage:not(:last-child):after{display:none}\r\n}\r\n@media(max-width:680px){\r\n body{font-size:16px}\r\n .shell{width:min(calc(100% - 20px),var(--max))}\r\n .top-actions .top-btn:first-child{display:none}\r\n .hero-grid{padding-top:42px}\r\n .hero-image{height:300px}\r\n .quick-wrap{margin-top:-18px}\r\n .quick-grid,.two-col,.scan-compare{grid-template-columns:1fr}\r\n .progression{grid-template-columns:1fr}\r\n .weight-row{grid-template-columns:1fr}\r\n .table-wrap{margin-left:-4px;margin-right:-4px}\r\n}\r\n<\/style>\r\n<\/head>\r\n\r\n<body>\r\n\r\n<header class=\"article-top\">\r\n <div class=\"shell article-top-inner\">\r\n <a class=\"article-brand\" href=\"https:\/\/uksono.com\/home\/health-articles\/\">\r\n <span class=\"brand-mark\">U<\/span>\r\n <span>\r\n <strong>UKSONO Health Articles<\/strong>\r\n <small>Medical Knowledge Centre<\/small>\r\n <\/span>\r\n <\/a>\r\n <nav class=\"top-actions\" aria-label=\"Article actions\">\r\n <a class=\"top-btn\" href=\"https:\/\/uksono.com\/home\/health-articles\/\">All Health Articles<\/a>\r\n <a class=\"top-btn primary\" href=\"https:\/\/uksono.com\/home\/liver-health-check-premium\/\">Explore Liver Health Checks<\/a>\r\n <\/nav>\r\n <\/div>\r\n<\/header>\r\n\r\n<div class=\"shell breadcrumbs\" aria-label=\"Breadcrumb\">\r\n <a href=\"https:\/\/uksono.com\/home\/\">Home<\/a> \u203a\r\n <a href=\"https:\/\/uksono.com\/home\/health-articles\/\">Health Articles<\/a> \u203a\r\n Fatty Liver Disease (MASLD)\r\n<\/div>\r\n\r\n<section class=\"hero\">\r\n <div class=\"shell hero-grid\">\r\n <div>\r\n <span class=\"hero-kicker\">Liver & Abdominal Health \u00b7 Article 01<\/span>\r\n <h1>Fatty Liver Disease <em>(MASLD)<\/em><\/h1>\r\n <p class=\"hero-lead\">\r\n A detailed guide to metabolic dysfunction-associated steatotic liver disease:\r\n what causes fat to accumulate in the liver, who is at risk, how blood tests and\r\n ultrasound contribute to diagnosis, how fibrosis is assessed and what you can do\r\n to reduce long-term liver and cardiovascular risk.\r\n <\/p>\r\n <div class=\"hero-meta\">\r\n <span>Clinically reviewed<\/span>\r\n <span>Ultrasound & elastography explained<\/span>\r\n <span>UK healthcare context<\/span>\r\n <span>Last reviewed: 8 August 2026<\/span>\r\n <\/div>\r\n <\/div>\r\n\r\n <figure class=\"hero-image\">\r\n <img src=\"https:\/\/uksono.com\/home\/wp-content\/uploads\/2024\/12\/Copy-of-Blue-and-White-Modern-Ultrasound-Clinic-Instagram-Post-900-x-471-mm.png\"\r\n alt=\"UKSONO liver health ultrasound and advanced liver assessment\"\r\n loading=\"eager\" decoding=\"async\">\r\n <figcaption class=\"hero-image-label\">\r\n <strong>Liver health is more than a single ultrasound image.<\/strong>\r\n <span>Assessment may combine liver morphology, fat estimation, fibrosis risk, elastography, blood tests and clinical risk factors.<\/span>\r\n <\/figcaption>\r\n <\/figure>\r\n <\/div>\r\n<\/section>\r\n\r\n<div class=\"shell quick-wrap\">\r\n <div class=\"quick-grid\">\r\n <div class=\"quick\">\r\n <small>Current term<\/small>\r\n <strong>MASLD<\/strong>\r\n <span>Metabolic dysfunction-associated steatotic liver disease; previously commonly called NAFLD.<\/span>\r\n <\/div>\r\n <div class=\"quick\">\r\n <small>Often silent<\/small>\r\n <strong>Few or no symptoms<\/strong>\r\n <span>Many people are diagnosed incidentally after blood tests or abdominal imaging.<\/span>\r\n <\/div>\r\n <div class=\"quick\">\r\n <small>Key prognostic issue<\/small>\r\n <strong>Fibrosis matters most<\/strong>\r\n <span>Long-term liver risk is driven more by fibrosis stage than by liver fat alone.<\/span>\r\n <\/div>\r\n <div class=\"quick\">\r\n <small>First-line approach<\/small>\r\n <strong>Risk-factor modification<\/strong>\r\n <span>Weight, diet, activity, diabetes, blood pressure, lipids and alcohol all matter.<\/span>\r\n <\/div>\r\n <\/div>\r\n<\/div>\r\n\r\n<main class=\"shell article-layout\">\r\n\r\n <aside class=\"toc\" aria-label=\"Article contents\">\r\n <b>In this article<\/b>\r\n <a href=\"#overview\">Overview<\/a>\r\n <a href=\"#liver-function\">What the liver does<\/a>\r\n <a href=\"#terminology\">MASLD terminology<\/a>\r\n <a href=\"#epidemiology\">Who is affected?<\/a>\r\n <a href=\"#causes\">Causes & risk factors<\/a>\r\n <a href=\"#symptoms\">Symptoms<\/a>\r\n <a href=\"#progression\">Stages & progression<\/a>\r\n <a href=\"#diagnosis\">Diagnosis & tests<\/a>\r\n <a href=\"#blood-tests\">Liver blood tests<\/a>\r\n <a href=\"#ultrasound\">Ultrasound findings<\/a>\r\n <a href=\"#quantification\">Fat quantification<\/a>\r\n <a href=\"#elastography\">Elastography & FibroScan<\/a>\r\n <a href=\"#ct-mri\">CT, MRI & biopsy<\/a>\r\n <a href=\"#treatment\">Treatment<\/a>\r\n <a href=\"#weight-loss\">Weight-loss targets<\/a>\r\n <a href=\"#medicines\">Medicines<\/a>\r\n <a href=\"#monitoring\">Monitoring & prognosis<\/a>\r\n <a href=\"#urgent\">When to seek help<\/a>\r\n <a href=\"#faq\">FAQs<\/a>\r\n <a href=\"#references\">References<\/a>\r\n <\/aside>\r\n\r\n <article class=\"article-content\">\r\n\r\n <section id=\"overview\">\r\n <h2>Overview: What is fatty liver disease?<\/h2>\r\n\r\n <div class=\"summary-box\">\r\n <strong>In simple terms:<\/strong>\r\n fatty liver means that excess fat has accumulated inside liver cells. When that\r\n steatosis occurs in a person with metabolic risk factors, and harmful alcohol intake\r\n or another primary cause does not better explain it, the modern term is\r\n <strong>metabolic dysfunction-associated steatotic liver disease (MASLD)<\/strong>.\r\n <\/div>\r\n\r\n <p>\r\n MASLD sits within a broader group of conditions called steatotic liver disease.\r\n Some people have fat in the liver without meaningful inflammation or scarring.\r\n Others develop metabolic dysfunction-associated steatohepatitis (MASH), where\r\n steatosis is accompanied by hepatocellular injury and inflammation. Persistent\r\n injury can lead to fibrosis, then cirrhosis in a smaller proportion of patients.\r\n <\/p>\r\n\r\n <p>\r\n The condition is closely linked to cardiometabolic health. Obesity, increased\r\n abdominal or visceral fat, insulin resistance, type 2 diabetes, dyslipidaemia and\r\n high blood pressure are important associations. This is why modern management\r\n focuses not only on the liver but also on cardiovascular, metabolic and kidney risk.\r\n <\/p>\r\n\r\n <p>\r\n Fatty liver is frequently discovered incidentally. A routine abdominal ultrasound\r\n may show a bright or echogenic liver, or blood tests may reveal an abnormal ALT,\r\n AST or GGT. Importantly, routine liver blood tests can be normal even when steatosis\r\n or clinically significant fibrosis is present. NICE specifically advises against\r\n using routine liver blood tests alone to rule out fatty liver disease or advanced\r\n fibrosis.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"liver-function\">\r\n <h2>What does the liver actually do?<\/h2>\r\n\r\n <p>\r\n The liver is one of the body's major metabolic organs. It sits predominantly in the\r\n right upper abdomen beneath the diaphragm and receives blood from both the hepatic\r\n artery and portal vein. Its functions are wide-ranging, which is why significant\r\n chronic liver disease can affect many systems.\r\n <\/p>\r\n\r\n <div class=\"two-col\">\r\n <div class=\"card\">\r\n <h3>Metabolism<\/h3>\r\n <p>\r\n The liver helps regulate glucose, cholesterol, triglycerides and amino acids.\r\n It stores glycogen and releases glucose when needed. It also converts and\r\n packages fats for transport.\r\n <\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <h3>Protein production<\/h3>\r\n <p>\r\n It produces albumin and many clotting factors. Falling albumin or a prolonged\r\n clotting time can be a sign of impaired synthetic function in advanced disease,\r\n although these usually remain normal in early MASLD.\r\n <\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <h3>Bile production<\/h3>\r\n <p>\r\n Bile made by the liver helps digest and absorb dietary fats. It travels through\r\n the intrahepatic and extrahepatic bile ducts before reaching the bowel.\r\n <\/p>\r\n <\/div>\r\n <div class=\"card\">\r\n <h3>Detoxification & processing<\/h3>\r\n <p>\r\n The liver metabolises many medicines, hormones and toxins and helps process\r\n bilirubin produced during red blood cell breakdown.\r\n <\/p>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"diagram\">\r\n <div class=\"diagram-title\">Simplified liver circulation and function<\/div>\r\n <svg viewBox=\"0 0 900 310\" role=\"img\" aria-label=\"Simplified diagram of liver blood supply and major functions\">\r\n <defs>\r\n <linearGradient id=\"liv\" x1=\"0\" y1=\"0\" x2=\"1\" y2=\"1\">\r\n <stop offset=\"0\" stop-color=\"#c96f55\"\/>\r\n <stop offset=\"1\" stop-color=\"#8f3e32\"\/>\r\n <\/linearGradient>\r\n <linearGradient id=\"ven\" x1=\"0\" y1=\"0\" x2=\"1\" y2=\"0\">\r\n <stop offset=\"0\" stop-color=\"#3159c7\"\/>\r\n <stop offset=\"1\" stop-color=\"#4f7cff\"\/>\r\n <\/linearGradient>\r\n <\/defs>\r\n <rect x=\"300\" y=\"58\" width=\"300\" height=\"185\" rx=\"90\" fill=\"url(#liv)\"\/>\r\n <text x=\"450\" y=\"142\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"28\" font-family=\"Arial\" font-weight=\"700\">LIVER<\/text>\r\n <text x=\"450\" y=\"173\" text-anchor=\"middle\" fill=\"#ffe9df\" font-size=\"15\" font-family=\"Arial\">metabolism \u00b7 synthesis \u00b7 bile \u00b7 detoxification<\/text>\r\n\r\n <path d=\"M120 96 C190 96 220 105 300 118\" stroke=\"url(#ven)\" stroke-width=\"18\" fill=\"none\" stroke-linecap=\"round\"\/>\r\n <text x=\"120\" y=\"70\" text-anchor=\"middle\" fill=\"#17325f\" font-size=\"15\" font-family=\"Arial\" font-weight=\"700\">Portal vein<\/text>\r\n <text x=\"120\" y=\"88\" text-anchor=\"middle\" fill=\"#627287\" font-size=\"11\" font-family=\"Arial\">nutrient-rich blood<\/text>\r\n\r\n <path d=\"M160 220 C220 205 245 195 305 180\" stroke=\"#c64a41\" stroke-width=\"11\" fill=\"none\" stroke-linecap=\"round\"\/>\r\n <text x=\"125\" y=\"248\" text-anchor=\"middle\" fill=\"#17325f\" font-size=\"15\" font-family=\"Arial\" font-weight=\"700\">Hepatic artery<\/text>\r\n <text x=\"125\" y=\"266\" text-anchor=\"middle\" fill=\"#627287\" font-size=\"11\" font-family=\"Arial\">oxygenated blood<\/text>\r\n\r\n <path d=\"M596 118 C675 108 715 96 790 96\" stroke=\"#4f7cff\" stroke-width=\"15\" fill=\"none\" stroke-linecap=\"round\"\/>\r\n <text x=\"784\" y=\"70\" text-anchor=\"middle\" fill=\"#17325f\" font-size=\"15\" font-family=\"Arial\" font-weight=\"700\">Hepatic veins<\/text>\r\n <text x=\"784\" y=\"88\" text-anchor=\"middle\" fill=\"#627287\" font-size=\"11\" font-family=\"Arial\">to the heart<\/text>\r\n\r\n <path d=\"M575 205 C660 220 700 235 777 245\" stroke=\"#c19b38\" stroke-width=\"10\" fill=\"none\" stroke-linecap=\"round\"\/>\r\n <text x=\"793\" y=\"230\" text-anchor=\"middle\" fill=\"#17325f\" font-size=\"15\" font-family=\"Arial\" font-weight=\"700\">Bile<\/text>\r\n <text x=\"793\" y=\"248\" text-anchor=\"middle\" fill=\"#627287\" font-size=\"11\" font-family=\"Arial\">to gallbladder \/ bowel<\/text>\r\n <\/svg>\r\n <div class=\"diagram-note\">Illustrative anatomy only; not intended to replace formal anatomical imaging.<\/div>\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"terminology\">\r\n <h2>Why is it called MASLD rather than NAFLD?<\/h2>\r\n\r\n <p>\r\n The terminology for fatty liver disease has changed. The older term\r\n <strong>non-alcoholic fatty liver disease (NAFLD)<\/strong> defined the condition\r\n largely by what it was not: significant alcohol-related disease. The newer\r\n terminology focuses more directly on the metabolic drivers of disease.\r\n <\/p>\r\n\r\n <div class=\"table-wrap\">\r\n <table>\r\n <thead>\r\n <tr><th>Older terminology<\/th><th>Current terminology<\/th><th>What it means<\/th><\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td>NAFLD<\/td>\r\n <td><strong>MASLD<\/strong><\/td>\r\n <td>Steatotic liver disease in a person with one or more cardiometabolic risk factors, without another dominant explanation such as harmful alcohol intake.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>NASH<\/td>\r\n <td><strong>MASH<\/strong><\/td>\r\n <td>Metabolic dysfunction-associated steatohepatitis: steatosis with hepatocellular injury and inflammation, which can promote fibrosis.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td>Alcohol-related \/ mixed categories<\/td>\r\n <td><strong>MetALD and ALD<\/strong><\/td>\r\n <td>Current nomenclature recognises that metabolic dysfunction and alcohol exposure can coexist rather than forcing every patient into a single binary category.<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n <p>\r\n You will still see NAFLD and NASH in older NICE guidance, research papers, clinic\r\n letters and imaging reports. The underlying clinical concepts overlap substantially,\r\n so a previous diagnosis of NAFLD does not suddenly become invalid because the\r\n terminology has changed.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"epidemiology\">\r\n <h2>How common is fatty liver disease?<\/h2>\r\n\r\n <p>\r\n MASLD is one of the most common chronic liver disorders worldwide. It is particularly\r\n common in people with type 2 diabetes, obesity and metabolic syndrome. NICE notes that\r\n NAFLD is present in more than half of adults with type 2 diabetes or metabolic syndrome\r\n in the evidence underpinning its research recommendations.\r\n <\/p>\r\n\r\n <p>\r\n Not everyone with liver fat develops advanced disease. The clinical challenge is\r\n identifying the smaller group with progressive inflammation and fibrosis. This is why\r\n modern pathways increasingly use staged risk assessment rather than treating every\r\n bright liver on ultrasound as equivalent.\r\n <\/p>\r\n\r\n <div class=\"clinical-box\">\r\n <strong>The important question is not simply \u201cDo I have fat in my liver?\u201d<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n A more useful question is: <em>\u201cDo I have evidence that the liver is being injured or\r\n scarred, and what cardiometabolic factors are driving that risk?\u201d<\/em>\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"causes\">\r\n <h2>What causes MASLD?<\/h2>\r\n\r\n <p>\r\n MASLD develops when energy and lipid handling become dysregulated and excess fat\r\n accumulates in hepatocytes. Insulin resistance plays a central role. Increased\r\n delivery of fatty acids from adipose tissue, increased production of fat within the\r\n liver and altered export or oxidation of fat all contribute.\r\n <\/p>\r\n\r\n <h3>Common risk factors<\/h3>\r\n\r\n <ul>\r\n <li>Overweight or obesity, especially increased abdominal or visceral fat.<\/li>\r\n <li>Type 2 diabetes or insulin resistance.<\/li>\r\n <li>High triglycerides or other dyslipidaemia.<\/li>\r\n <li>High blood pressure.<\/li>\r\n <li>Metabolic syndrome.<\/li>\r\n <li>Polycystic ovary syndrome (PCOS), particularly where insulin resistance is present.<\/li>\r\n <li>Obstructive sleep apnoea and other conditions associated with metabolic dysfunction.<\/li>\r\n <li>Low physical activity and diets high in ultra-processed foods or sugar-sweetened drinks.<\/li>\r\n <li>Family\/genetic susceptibility.<\/li>\r\n <\/ul>\r\n\r\n <h3>Can lean people develop MASLD?<\/h3>\r\n\r\n <p>\r\n Yes. MASLD is not restricted to people with obesity. The 2024 European guideline\r\n recognises normal-weight MASLD. A person can have a BMI within the normal range but\r\n still have increased visceral adiposity, insulin resistance, reduced muscle mass or\r\n genetic susceptibility. For that reason, body weight is an important risk marker but\r\n not the whole story.\r\n <\/p>\r\n\r\n <div class=\"myth-box\">\r\n <strong>Myth: \u201cFatty liver only happens because somebody is overweight.\u201d<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n Weight is important, but MASLD is a metabolic condition influenced by fat\r\n distribution, insulin sensitivity, genetics, diet, activity, age and other\r\n cardiometabolic factors.\r\n <\/p>\r\n <\/div>\r\n\r\n <h3>What about alcohol?<\/h3>\r\n\r\n <p>\r\n Alcohol history remains important. Significant alcohol exposure can itself cause\r\n steatosis and progressive liver disease, and alcohol can add to metabolic liver risk.\r\n The newer nomenclature recognises overlap categories such as MetALD. Patients should\r\n give clinicians an accurate alcohol history rather than assuming that a diagnosis of\r\n \u201cfatty liver\u201d automatically means alcohol is irrelevant.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"symptoms\">\r\n <h2>What are the symptoms of fatty liver disease?<\/h2>\r\n\r\n <p>\r\n Most people with early MASLD have no specific symptoms. The NHS notes that many\r\n people are diagnosed only because blood tests or scans were performed for another\r\n reason.\r\n <\/p>\r\n\r\n <div class=\"two-col\">\r\n <div class=\"card\">\r\n <h3>Possible early symptoms<\/h3>\r\n <ul>\r\n <li>Persistent tiredness or low energy.<\/li>\r\n <li>A general sense of being unwell.<\/li>\r\n <li>Right upper abdominal discomfort beneath the ribs.<\/li>\r\n <li>Symptoms related to associated diabetes or metabolic disease rather than the liver itself.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <div class=\"card\">\r\n <h3>Symptoms of advanced disease<\/h3>\r\n <ul>\r\n <li>Abdominal swelling from ascites.<\/li>\r\n <li>Leg swelling.<\/li>\r\n <li>Jaundice.<\/li>\r\n <li>Easy bruising or bleeding.<\/li>\r\n <li>Muscle loss or weight loss.<\/li>\r\n <li>Confusion or altered concentration in decompensated disease.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"warning-box\">\r\n <strong>Symptoms are a poor screening test for liver fibrosis.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n A person can have clinically important fibrosis while feeling well. Conversely,\r\n fatigue or abdominal discomfort can have many causes unrelated to the liver.\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"progression\">\r\n <h2>Stages of fatty liver disease<\/h2>\r\n\r\n <p>\r\n Fatty liver disease exists on a spectrum. Progression is not inevitable, and patients\r\n may move in either direction depending on metabolic control, weight, alcohol exposure,\r\n treatment and individual susceptibility.\r\n <\/p>\r\n\r\n <div class=\"diagram\">\r\n <div class=\"diagram-title\">Simplified MASLD disease spectrum<\/div>\r\n <div class=\"progression\">\r\n <div class=\"stage\">\r\n <span class=\"stage-num\">1<\/span>\r\n <b>Steatosis<\/b>\r\n <span>Excess fat accumulates in liver cells without established advanced scarring.<\/span>\r\n <\/div>\r\n <div class=\"stage\">\r\n <span class=\"stage-num\">2<\/span>\r\n <b>MASH<\/b>\r\n <span>Steatosis is accompanied by hepatocellular injury and inflammation.<\/span>\r\n <\/div>\r\n <div class=\"stage\">\r\n <span class=\"stage-num\">3<\/span>\r\n <b>Fibrosis<\/b>\r\n <span>Persistent injury stimulates deposition of scar tissue within the liver.<\/span>\r\n <\/div>\r\n <div class=\"stage\">\r\n <span class=\"stage-num\">4<\/span>\r\n <b>Cirrhosis<\/b>\r\n <span>Advanced architectural distortion increases risks such as portal hypertension and liver cancer.<\/span>\r\n <\/div>\r\n <\/div>\r\n <div class=\"diagram-note\">This is a simplified clinical model. Histological staging is more detailed and individual progression rates vary.<\/div>\r\n <\/div>\r\n\r\n <h3>Why fibrosis matters<\/h3>\r\n\r\n <p>\r\n Liver fat can fluctuate relatively quickly with metabolic changes. Fibrosis reflects\r\n a longer-term wound-healing response to persistent injury. Advanced fibrosis is a\r\n stronger predictor of liver-related outcomes than steatosis alone, so fibrosis\r\n assessment is an important part of modern MASLD care.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"diagnosis\">\r\n <h2>How is MASLD diagnosed?<\/h2>\r\n\r\n <p>\r\n There is no single test that answers every question. Diagnosis usually combines the\r\n clinical history, cardiometabolic risk profile, alcohol assessment, liver blood tests\r\n and imaging. Additional blood tests may be used to exclude alternative causes of\r\n liver disease.\r\n <\/p>\r\n\r\n <h3>A typical diagnostic pathway<\/h3>\r\n\r\n <ol>\r\n <li><strong>Identify steatosis or risk:<\/strong> abnormal ultrasound, abnormal liver blood tests or significant cardiometabolic risk.<\/li>\r\n <li><strong>Review alternative causes:<\/strong> alcohol, medicines, viral hepatitis, autoimmune disease, haemochromatosis and other relevant conditions depending on the presentation.<\/li>\r\n <li><strong>Assess fibrosis risk:<\/strong> blood-based scores such as FIB-4 or other locally used tests.<\/li>\r\n <li><strong>Use second-line fibrosis testing where indicated:<\/strong> transient elastography, shear-wave elastography, ARFI-based techniques or ELF depending on local pathways.<\/li>\r\n <li><strong>Refer higher-risk patients:<\/strong> hepatology assessment when advanced fibrosis, cirrhosis, diagnostic uncertainty or another concerning feature is present.<\/li>\r\n <\/ol>\r\n\r\n <p>\r\n The 2024 EASL\u2013EASD\u2013EASO guideline supports case-finding for liver fibrosis in people\r\n with cardiometabolic risk factors, abnormal liver enzymes and\/or radiological\r\n steatosis, with particular attention to type 2 diabetes and obesity with additional\r\n metabolic risk factors. A staged approach using FIB-4 followed by imaging-based\r\n elastography is specifically highlighted.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"blood-tests\">\r\n <h2>Liver blood tests explained<\/h2>\r\n\r\n <p>\r\n \u201cLiver function tests\u201d is a convenient phrase, but not every component directly\r\n measures liver function. Some markers reflect hepatocellular injury, others\r\n cholestasis, and others synthetic capacity. Interpretation depends on the pattern,\r\n degree of abnormality and clinical context.\r\n <\/p>\r\n\r\n <div class=\"table-wrap\">\r\n <table>\r\n <thead>\r\n <tr><th>Test<\/th><th>What it broadly reflects<\/th><th>How it can relate to MASLD<\/th><\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td><strong>ALT<\/strong><\/td>\r\n <td>Hepatocellular injury<\/td>\r\n <td>May be raised in MASH or other liver injury, but can be normal despite steatosis or fibrosis.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>AST<\/strong><\/td>\r\n <td>Hepatocellular injury; also found outside the liver<\/td>\r\n <td>Patterns and ratios may change as disease advances, but AST is not specific to MASLD.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>ALP<\/strong><\/td>\r\n <td>Cholestatic\/biliary processes; also bone<\/td>\r\n <td>A marked isolated rise should prompt consideration of biliary or non-hepatic causes rather than being attributed automatically to fatty liver.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>GGT<\/strong><\/td>\r\n <td>Enzyme induction \/ cholestatic pattern<\/td>\r\n <td>Can be raised in metabolic liver disease and with alcohol or medicines; it is not specific.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Bilirubin<\/strong><\/td>\r\n <td>Bilirubin production, hepatic processing and excretion<\/td>\r\n <td>Usually normal in uncomplicated early MASLD. Jaundice requires investigation.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Albumin<\/strong><\/td>\r\n <td>Hepatic protein synthesis, but affected by other conditions<\/td>\r\n <td>Often normal until advanced liver disease; low albumin has a broad differential diagnosis.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>INR \/ prothrombin time<\/strong><\/td>\r\n <td>Clotting-factor synthesis<\/td>\r\n <td>Prolongation can signal reduced hepatic synthetic reserve in advanced disease, although anticoagulants and other factors must be considered.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Platelets<\/strong><\/td>\r\n <td>Not a liver enzyme; useful in fibrosis risk scores<\/td>\r\n <td>A falling platelet count can be seen with portal hypertension and is incorporated into FIB-4.<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n <div class=\"info-box\">\r\n <strong>Normal ALT does not equal a normal liver.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n NICE advises that routine liver blood tests should not be used to rule out fatty\r\n liver disease or advanced fibrosis. Imaging and fibrosis risk assessment may still\r\n be appropriate when the clinical risk is significant.\r\n <\/p>\r\n <\/div>\r\n\r\n <h3>What is FIB-4?<\/h3>\r\n\r\n <p>\r\n FIB-4 is a simple fibrosis risk score derived from age, AST, ALT and platelet count.\r\n It is useful as a first-stage risk stratification tool rather than as a definitive\r\n diagnosis. Thresholds require age-aware interpretation and local clinical pathways.\r\n Intermediate or high-risk results often prompt a second-line test such as elastography\r\n or ELF.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"ultrasound\">\r\n <h2>What does fatty liver look like on ultrasound?<\/h2>\r\n\r\n <p>\r\n Conventional B-mode ultrasound is widely used because it is non-invasive, accessible,\r\n does not use ionising radiation and can assess the liver together with the gallbladder,\r\n bile ducts, kidneys, spleen and other upper abdominal structures.\r\n <\/p>\r\n\r\n <h3>Typical ultrasound features of hepatic steatosis<\/h3>\r\n\r\n <ul>\r\n <li><strong>Increased liver echogenicity:<\/strong> the liver appears brighter than expected, often compared with the right renal cortex when the kidney is suitable for comparison.<\/li>\r\n <li><strong>Reduced visualisation of intrahepatic vessels:<\/strong> vessel walls and deeper vascular detail may become less conspicuous.<\/li>\r\n <li><strong>Posterior beam attenuation:<\/strong> ultrasound penetration decreases with depth, making the deep liver and diaphragm harder to see.<\/li>\r\n <li><strong>Reduced diaphragm definition:<\/strong> in more marked steatosis the posterior liver-diaphragm interface may be less distinct.<\/li>\r\n <li><strong>Hepatomegaly:<\/strong> some patients have an enlarged liver, although size alone is not diagnostic of steatosis.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"scan-compare\">\r\n <div class=\"scan-panel normal\">\r\n <div class=\"scan-screen\"><\/div>\r\n <b>Illustrative normal echotexture<\/b>\r\n <span>Relatively homogeneous parenchyma with preserved deep penetration and vascular definition.<\/span>\r\n <\/div>\r\n <div class=\"scan-panel fatty\">\r\n <div class=\"scan-screen\"><\/div>\r\n <b>Illustrative fatty liver appearance<\/b>\r\n <span>Increased echogenicity and progressively reduced visibility of deeper structures as steatosis becomes more marked.<\/span>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"clinical-box\">\r\n <strong>Ultrasound does not diagnose MASH.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n Conventional ultrasound can identify or suggest steatosis and assess morphology,\r\n but it cannot reliably determine whether microscopic steatohepatitis is present.\r\n That distinction relates to hepatocellular injury and inflammation, historically\r\n established with histology when tissue diagnosis is required.\r\n <\/p>\r\n <\/div>\r\n\r\n <h3>Can ultrasound grade mild, moderate and severe fatty liver?<\/h3>\r\n\r\n <p>\r\n Sonographers may describe the visual severity of steatosis, but conventional\r\n qualitative grading has limitations. It is affected by machine settings, body\r\n habitus, fibrosis, operator technique and the subjective nature of comparing\r\n echogenicity. Modern quantitative attenuation techniques aim to provide a more\r\n reproducible estimate of liver fat.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"quantification\">\r\n <h2>Quantitative ultrasound fat assessment<\/h2>\r\n\r\n <p>\r\n Newer ultrasound platforms can estimate how strongly the liver attenuates the\r\n ultrasound beam. Because fat changes acoustic attenuation, these measurements can\r\n provide an objective parameter related to steatosis rather than relying only on a\r\n visual \u201cbright liver\u201d impression.\r\n <\/p>\r\n\r\n <h3>UGAP and attenuation-based techniques<\/h3>\r\n\r\n <p>\r\n Ultrasound-guided attenuation parameter (UGAP) and similar vendor-specific methods\r\n measure attenuation within a defined liver region of interest. The result is usually\r\n expressed in attenuation units such as dB\/cm\/MHz. Thresholds vary by technology and\r\n validation study, so results must be interpreted using the correct manufacturer and\r\n evidence base rather than applying one machine's cut-off to another.\r\n <\/p>\r\n\r\n <p>\r\n Quantitative fat assessment can be useful for baseline characterisation and\r\n longitudinal monitoring, particularly when performed on the same platform under\r\n similar conditions. It does not by itself tell you the fibrosis stage or prove MASH.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"elastography\">\r\n <h2>Elastography, liver stiffness and FibroScan<\/h2>\r\n\r\n <p>\r\n Elastography estimates tissue stiffness. In chronic liver disease, fibrosis tends to\r\n increase liver stiffness, which makes elastography useful for non-invasive fibrosis\r\n risk assessment.\r\n <\/p>\r\n\r\n <h3>Shear-wave elastography (SWE)<\/h3>\r\n\r\n <p>\r\n Shear-wave elastography uses ultrasound-generated shear waves and measures their\r\n propagation through the liver. Results may be displayed in metres per second (m\/s)\r\n or converted to kilopascals (kPa). The examination is performed using defined\r\n quality criteria, typically through an intercostal window with a region of interest\r\n placed in appropriate liver parenchyma away from large vessels and artefacts.\r\n <\/p>\r\n\r\n <h3>FibroScan \/ vibration-controlled transient elastography<\/h3>\r\n\r\n <p>\r\n FibroScan uses vibration-controlled transient elastography to estimate liver\r\n stiffness. NICE HealthTech guidance recognises FibroScan as a non-invasive method for\r\n assessing fibrosis and cirrhosis in defined pathways. FibroScan can also provide a\r\n controlled attenuation parameter (CAP) to estimate steatosis.\r\n <\/p>\r\n\r\n <div class=\"warning-box\">\r\n <strong>A stiffness result is not a biopsy stage printed by a machine.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n Liver stiffness is influenced by fibrosis but can also rise with active\r\n inflammation, cholestasis, hepatic congestion, recent food intake and technical\r\n factors. Cut-offs vary by disease population and technology. The result should be\r\n interpreted with the clinical context and quality metrics.\r\n <\/p>\r\n <\/div>\r\n\r\n <h3>Why use both fat and stiffness measurements?<\/h3>\r\n\r\n <p>\r\n They answer different questions. Attenuation-based measures estimate the amount of\r\n steatosis; elastography estimates stiffness and therefore fibrosis risk. A patient\r\n can have substantial fat with little fibrosis, or less obvious fat but clinically\r\n important fibrosis after years of disease.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"ct-mri\">\r\n <h2>CT, MRI and liver biopsy: when are they used?<\/h2>\r\n\r\n <div class=\"table-wrap\">\r\n <table>\r\n <thead>\r\n <tr><th>Test<\/th><th>Strengths<\/th><th>Important limitations<\/th><\/tr>\r\n <\/thead>\r\n <tbody>\r\n <tr>\r\n <td><strong>Ultrasound<\/strong><\/td>\r\n <td>Accessible, no ionising radiation, assesses liver morphology and other abdominal organs; can be combined with Doppler, attenuation imaging and elastography.<\/td>\r\n <td>Mild steatosis may be difficult to detect; qualitative grading is subjective; image quality can be limited by body habitus and bowel gas.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>CT<\/strong><\/td>\r\n <td>Can demonstrate steatosis and is excellent for many complications or alternative abdominal diagnoses.<\/td>\r\n <td>Uses ionising radiation and is not usually performed simply to screen for uncomplicated fatty liver.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>MRI \/ MRI-PDFF<\/strong><\/td>\r\n <td>Highly accurate non-invasive quantification of liver fat; MR elastography can assess fibrosis.<\/td>\r\n <td>More expensive, less accessible, and not required for most routine cases.<\/td>\r\n <\/tr>\r\n <tr>\r\n <td><strong>Liver biopsy<\/strong><\/td>\r\n <td>Can directly assess steatosis, inflammation, ballooning and fibrosis and remains important in selected diagnostic dilemmas.<\/td>\r\n <td>Invasive, carries procedural risk and sampling variability; unsuitable as a population screening test.<\/td>\r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n\r\n <p>\r\n Cross-sectional imaging or biopsy is generally reserved for situations where it will\r\n answer a clinically important question not adequately resolved by routine\r\n non-invasive assessment.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"treatment\">\r\n <h2>How is fatty liver disease treated?<\/h2>\r\n\r\n <p>\r\n Treatment is personalised according to fibrosis risk, body weight, diabetes status,\r\n cardiovascular risk, alcohol intake and other comorbidities. There is no single\r\n universal \u201cfatty liver cure.\u201d The foundation is reducing the metabolic drivers of\r\n liver injury.\r\n <\/p>\r\n\r\n <h3>1. Improve diet quality<\/h3>\r\n\r\n <p>\r\n The 2024 European MASLD guideline recommends improving diet quality in a pattern\r\n similar to a Mediterranean diet, limiting ultra-processed foods rich in sugar and\r\n saturated fat, and avoiding sugar-sweetened beverages. The practical goal is a\r\n sustainable eating pattern rather than a short restrictive \u201cliver detox.\u201d\r\n <\/p>\r\n\r\n <h3>2. Exercise regularly<\/h3>\r\n\r\n <p>\r\n Physical activity can reduce liver fat and improve insulin sensitivity even when\r\n weight loss is modest. The NHS advises aiming for at least 150 minutes of exercise\r\n each week for people with fatty liver disease, adapted to individual health and\r\n capability.\r\n <\/p>\r\n\r\n <h3>3. Manage diabetes, lipids and blood pressure<\/h3>\r\n\r\n <p>\r\n Cardiovascular disease is a major source of morbidity in MASLD. Optimal management\r\n of type 2 diabetes, hypertension and dyslipidaemia is therefore central to treatment,\r\n not an optional extra.\r\n <\/p>\r\n\r\n <h3>4. Address alcohol intake<\/h3>\r\n\r\n <p>\r\n Alcohol can compound liver injury. Patients with MASLD should discuss alcohol\r\n exposure with their healthcare professional, particularly if fibrosis is present.\r\n NHS advice for the general population remains not to exceed 14 units per week, but a\r\n lower or zero intake may be appropriate for some people with liver disease.\r\n <\/p>\r\n\r\n <h3>5. Stop smoking<\/h3>\r\n\r\n <p>\r\n Smoking increases cardiovascular and cancer risk and undermines overall metabolic\r\n health. Stopping smoking is one of the most valuable long-term health interventions\r\n a person can make.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"weight-loss\">\r\n <h2>How much weight loss improves fatty liver?<\/h2>\r\n\r\n <p>\r\n When a person with MASLD is overweight, the magnitude of sustained weight loss\r\n matters. The 2024 EASL\u2013EASD\u2013EASO guideline gives useful evidence-based targets:\r\n <\/p>\r\n\r\n <div class=\"diagram\">\r\n <div class=\"diagram-title\">Weight-loss targets associated with liver improvement<\/div>\r\n <div class=\"weight-bars\">\r\n <div class=\"weight-row\">\r\n <div class=\"weight-label\">\u22655%<\/div>\r\n <div class=\"bar\"><i style=\"width:45%\"><\/i><\/div>\r\n <div class=\"weight-note\">Target associated with reduction in liver fat.<\/div>\r\n <\/div>\r\n <div class=\"weight-row\">\r\n <div class=\"weight-label\">7\u201310%<\/div>\r\n <div class=\"bar\"><i style=\"width:72%\"><\/i><\/div>\r\n <div class=\"weight-note\">Target associated with improvement in liver inflammation.<\/div>\r\n <\/div>\r\n <div class=\"weight-row\">\r\n <div class=\"weight-label\">\u226510%<\/div>\r\n <div class=\"bar\"><i style=\"width:100%\"><\/i><\/div>\r\n <div class=\"weight-note\">Target associated with the greatest likelihood of fibrosis improvement.<\/div>\r\n <\/div>\r\n <\/div>\r\n <div class=\"diagram-note\">These are population-level therapeutic targets from European guidance, not a guarantee of individual histological response.<\/div>\r\n <\/div>\r\n\r\n <p>\r\n Weight loss should be safe, sustainable and individualised. Rapid crash diets can be\r\n difficult to maintain and may be unsuitable for some patients. People with advanced\r\n liver disease, frailty, eating disorders, pregnancy or major medical conditions\r\n should seek personalised advice before undertaking a significant weight-loss plan.\r\n <\/p>\r\n\r\n <div class=\"info-box\">\r\n <strong>Normal-weight MASLD still benefits from lifestyle improvement.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n European guidance recommends diet and exercise interventions even in normal-weight\r\n adults with MASLD because liver fat can improve without obesity being present.\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"medicines\">\r\n <h2>Are there medicines for MASLD or MASH?<\/h2>\r\n\r\n <p>\r\n Pharmacological treatment is evolving rapidly. Medicines may be prescribed primarily\r\n for obesity, diabetes, cardiovascular risk or selected liver indications. Treatment\r\n should be clinician-led rather than based on a scan result alone.\r\n <\/p>\r\n\r\n <h3>GLP-1 receptor agonists and incretin-based therapy<\/h3>\r\n\r\n <p>\r\n Medicines such as semaglutide and tirzepatide may be indicated for type 2 diabetes or\r\n obesity in appropriate patients and can produce substantial weight loss and metabolic\r\n improvement. European guidance supports their use for their licensed metabolic\r\n indications in people with MASLD, while distinguishing this from recommending every\r\n GLP-1 drug as a direct MASH-targeted therapy.\r\n <\/p>\r\n\r\n <h3>Resmetirom<\/h3>\r\n\r\n <p>\r\n Resmetirom has been approved in some jurisdictions for selected adults with\r\n non-cirrhotic MASH and significant fibrosis. Availability and licensing vary by\r\n country, and treatment decisions require specialist assessment. It should not be\r\n viewed as a general treatment for everyone with an ultrasound diagnosis of fatty\r\n liver.\r\n <\/p>\r\n\r\n <h3>Pioglitazone, vitamin E and other treatments<\/h3>\r\n\r\n <p>\r\n Older guidelines and selected specialist pathways discuss pioglitazone or vitamin E\r\n for particular groups. Evidence and recommendations depend on diabetes status,\r\n fibrosis stage, age and setting. These should not be self-started for fatty liver.\r\n <\/p>\r\n\r\n <div class=\"warning-box\">\r\n <strong>Avoid unregulated \u201cliver detox\u201d supplements.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n \u201cNatural\u201d does not mean liver-safe. Herbal and dietary supplements can themselves\r\n cause liver injury or interact with prescribed medication. Discuss supplements\r\n with a pharmacist, GP or liver specialist.\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"monitoring\">\r\n <h2>Monitoring, follow-up and prognosis<\/h2>\r\n\r\n <p>\r\n Monitoring should be driven by fibrosis risk and metabolic health rather than\r\n repeating a conventional ultrasound at arbitrary intervals. Follow-up may include\r\n weight, blood pressure, HbA1c\/glucose, lipid profile, liver blood tests, fibrosis\r\n scores and repeat non-invasive fibrosis assessment.\r\n <\/p>\r\n\r\n <p>\r\n NICE recommends assessment for advanced liver fibrosis in people diagnosed with\r\n NAFLD. Its current NG49 pathway uses the ELF test, with specialist referral for\r\n advanced fibrosis. In real-world UK practice, availability varies, and FibroScan or\r\n other elastography techniques are frequently used alongside blood-based risk scores.\r\n <\/p>\r\n\r\n <h3>What determines prognosis?<\/h3>\r\n\r\n <ul>\r\n <li>Fibrosis stage.<\/li>\r\n <li>Presence and control of type 2 diabetes.<\/li>\r\n <li>Obesity and visceral adiposity.<\/li>\r\n <li>Cardiovascular disease and overall metabolic risk.<\/li>\r\n <li>Alcohol exposure.<\/li>\r\n <li>Age and other liver diseases.<\/li>\r\n <li>Whether lifestyle and metabolic risk factors improve over time.<\/li>\r\n <\/ul>\r\n\r\n <p>\r\n Early steatosis can improve substantially. Advanced fibrosis and cirrhosis require\r\n closer specialist follow-up because risks include portal hypertension, liver\r\n decompensation and hepatocellular carcinoma. NICE recommends six-monthly liver\r\n ultrasound surveillance for hepatocellular carcinoma in people with cirrhosis\r\n without hepatitis B, with or without serum AFP according to the pathway.\r\n <\/p>\r\n <\/section>\r\n\r\n <section id=\"urgent\">\r\n <h2>When should you seek medical help?<\/h2>\r\n\r\n <h3>Arrange routine medical review if:<\/h3>\r\n <ul>\r\n <li>An ultrasound reports hepatic steatosis or features of chronic liver disease.<\/li>\r\n <li>Liver enzymes remain abnormal on repeat testing.<\/li>\r\n <li>You have type 2 diabetes, obesity or metabolic syndrome and are concerned about liver risk.<\/li>\r\n <li>You have unexplained persistent right upper abdominal discomfort or fatigue.<\/li>\r\n <li>A fibrosis score or elastography result is abnormal or indeterminate.<\/li>\r\n <\/ul>\r\n\r\n <div class=\"warning-box\">\r\n <strong>Seek urgent medical assessment for possible advanced liver complications.<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n New jaundice, vomiting blood, black stools, marked abdominal swelling, confusion,\r\n collapse, severe persistent abdominal pain or rapidly worsening illness should not\r\n wait for a routine private ultrasound appointment.\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"faq\" class=\"faq\">\r\n <h2>Frequently asked questions<\/h2>\r\n\r\n <details>\r\n <summary>Can fatty liver be seen on ultrasound?<\/summary>\r\n <p>\r\n Yes. Moderate or marked hepatic steatosis often produces characteristic increased\r\n echogenicity and attenuation. Mild steatosis may be less conspicuous, and image\r\n quality can be affected by body habitus and other technical factors.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>Can I have fatty liver with normal ALT and AST?<\/summary>\r\n <p>\r\n Yes. Normal routine liver enzymes do not exclude steatosis or fibrosis. NICE\r\n specifically advises against using routine liver blood tests alone to rule out\r\n fatty liver disease or advanced fibrosis.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>Does fatty liver always progress to cirrhosis?<\/summary>\r\n <p>\r\n No. Many people remain at the steatosis stage, particularly when metabolic risk\r\n factors are improved. A smaller group develops progressive inflammation and\r\n fibrosis. Fibrosis risk assessment helps identify people who need closer follow-up.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>Can fatty liver be reversed?<\/summary>\r\n <p>\r\n Liver fat can fall substantially with sustained improvements in weight, diet,\r\n physical activity and metabolic control. MASH can also improve. Fibrosis can regress\r\n in some people, but advanced fibrosis is more difficult to reverse, which is why\r\n early intervention matters.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>What is the difference between fatty liver and fibrosis?<\/summary>\r\n <p>\r\n Steatosis describes excess fat within liver cells. Fibrosis is scar tissue produced\r\n after persistent injury. A person can have significant steatosis with little\r\n fibrosis, or advanced fibrosis after years of liver injury even when current fat\r\n levels are less striking.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>Does a conventional liver ultrasound tell me my fibrosis stage?<\/summary>\r\n <p>\r\n Not reliably. Advanced chronic liver disease may produce morphological signs on\r\n B-mode ultrasound, but early fibrosis cannot be staged accurately from brightness\r\n or texture alone. Elastography and\/or validated blood-based tests are used for\r\n non-invasive fibrosis risk assessment.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>What is the difference between FibroScan and shear-wave elastography?<\/summary>\r\n <p>\r\n Both are non-invasive elastography methods used to estimate liver stiffness.\r\n FibroScan uses vibration-controlled transient elastography, whereas shear-wave\r\n elastography is integrated into many diagnostic ultrasound systems. They have\r\n different acquisition methods and validated cut-offs, so results are not\r\n interchangeable without context.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>Is fatty liver caused by eating fat?<\/summary>\r\n <p>\r\n The biology is more complex. MASLD reflects disordered energy metabolism and\r\n insulin resistance, influenced by calorie excess, visceral adiposity, dietary\r\n composition, genetics and physical activity. Simply removing all dietary fat is not\r\n the recommended treatment.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>Should I stop alcohol completely?<\/summary>\r\n <p>\r\n This depends on your liver status and overall risk. Alcohol can add to metabolic\r\n liver injury. People with fibrosis or cirrhosis should discuss alcohol specifically\r\n with their clinician; abstinence may be advised.\r\n <\/p>\r\n <\/details>\r\n\r\n <details>\r\n <summary>How often should liver elastography be repeated?<\/summary>\r\n <p>\r\n There is no single interval appropriate for every person. Repeat testing depends on\r\n baseline fibrosis risk, diabetes and metabolic control, changes in weight, abnormal\r\n blood tests and specialist recommendations.\r\n <\/p>\r\n <\/details>\r\n <\/section>\r\n\r\n <section>\r\n <h2>How UKSONO Healthcare can help<\/h2>\r\n\r\n <p>\r\n A useful liver assessment should answer more than \u201cis the liver bright?\u201d Depending on\r\n the selected UKSONO liver-health package and clinical indication, assessment can\r\n combine diagnostic liver ultrasound with advanced non-invasive methods for liver fat\r\n and fibrosis risk, plus selected blood testing.\r\n <\/p>\r\n\r\n <div class=\"two-col\">\r\n <div class=\"card\">\r\n <h3>Structural assessment<\/h3>\r\n <ul>\r\n <li>Liver morphology and echotexture.<\/li>\r\n <li>Gallbladder and biliary tract.<\/li>\r\n <li>Portal and hepatic venous appearances where relevant.<\/li>\r\n <li>Spleen, ascites and features that may suggest portal hypertension.<\/li>\r\n <li>Focal liver lesions visible on ultrasound.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <div class=\"card\">\r\n <h3>Advanced liver assessment<\/h3>\r\n <ul>\r\n <li>Quantitative attenuation \/ liver-fat assessment where included.<\/li>\r\n <li>Shear-wave elastography \/ stiffness assessment where included.<\/li>\r\n <li>FibroScan-type pathways depending on package\/location.<\/li>\r\n <li>Selected blood tests and metabolic risk assessment.<\/li>\r\n <li>Clear recommendations for GP or hepatology follow-up when indicated.<\/li>\r\n <\/ul>\r\n <\/div>\r\n <\/div>\r\n\r\n <div class=\"booking\">\r\n <h2>Concerned about fatty liver or liver fibrosis?<\/h2>\r\n <p>\r\n Explore UKSONO Healthcare's advanced liver health checks for assessment options,\r\n preparation guidance, locations and current package details.\r\n <\/p>\r\n <a href=\"https:\/\/uksono.com\/home\/liver-health-check-premium\/\">Explore Advanced Liver Health Checks<\/a>\r\n <small>Tunbridge Wells \u00b7 Orpington \u00b7 Canary Wharf \u00b7 01892 251532<\/small>\r\n <\/div>\r\n\r\n <div class=\"reviewer\">\r\n <small>Clinical review<\/small>\r\n <strong>Christopher U. Agu MSc, PGDip, BSc<\/strong>\r\n <span>Clinical Lead \/ Consultant Sonographer, UKSONO Healthcare<\/span>\r\n <span>Last reviewed: 8 August 2026<\/span>\r\n <\/div>\r\n\r\n <div class=\"disclaimer\">\r\n <strong>Medical disclaimer:<\/strong>\r\n This article is for education and does not replace personalised medical advice.\r\n Diagnostic pathways and treatment recommendations depend on the individual clinical\r\n context. If you have persistent, worsening or urgent symptoms, seek assessment from an\r\n appropriate healthcare professional.\r\n <\/div>\r\n <\/section>\r\n\r\n <section id=\"references\" class=\"references\">\r\n <h2>References & further reading<\/h2>\r\n\r\n <ol>\r\n <li>\r\n European Association for the Study of the Liver (EASL), European Association for\r\n the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO).\r\n <em>EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic\r\n dysfunction-associated steatotic liver disease (MASLD).<\/em> Journal of Hepatology.\r\n 2024;81(3):492\u2013542.\r\n <a href=\"https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(24)00329-5\/fulltext\" target=\"_blank\" rel=\"noopener\">View guideline<\/a>.\r\n <\/li>\r\n <li>\r\n NICE. <em>Non-alcoholic fatty liver disease (NAFLD): assessment and management\r\n (NG49).<\/em> Published 2016; reviewed 2024.\r\n <a href=\"https:\/\/www.nice.org.uk\/guidance\/ng49\" target=\"_blank\" rel=\"noopener\">View NICE guidance<\/a>.\r\n <\/li>\r\n <li>\r\n NICE. <em>Cirrhosis in over 16s: assessment and management (NG50).<\/em>\r\n Last updated September 2023.\r\n <a href=\"https:\/\/www.nice.org.uk\/guidance\/ng50\" target=\"_blank\" rel=\"noopener\">View NICE guidance<\/a>.\r\n <\/li>\r\n <li>\r\n NICE. <em>FibroScan for assessing liver fibrosis and cirrhosis outside secondary and\r\n specialist care (HTG682).<\/em> 2023.\r\n <a href=\"https:\/\/www.nice.org.uk\/guidance\/htg682\" target=\"_blank\" rel=\"noopener\">View NICE HealthTech guidance<\/a>.\r\n <\/li>\r\n <li>\r\n NHS. <em>Non-alcoholic fatty liver disease (NAFLD).<\/em>\r\n <a href=\"https:\/\/www.nhs.uk\/conditions\/non-alcoholic-fatty-liver-disease\/\" target=\"_blank\" rel=\"noopener\">View NHS patient information<\/a>.\r\n <\/li>\r\n <li>\r\n NICE. <em>MRI-based technologies for assessing non-alcoholic fatty liver disease\r\n (HTG655).<\/em> 2023.\r\n <a href=\"https:\/\/www.nice.org.uk\/guidance\/htg655\" target=\"_blank\" rel=\"noopener\">View NICE HealthTech guidance<\/a>.\r\n <\/li>\r\n <\/ol>\r\n\r\n <div class=\"clinical-box\">\r\n <strong>Editorial note:<\/strong>\r\n <p style=\"margin:7px 0 0\">\r\n The terminology and evidence base for steatotic liver disease are evolving.\r\n UKSONO articles should be periodically reviewed against updated NICE, NHS, EASL,\r\n BSG and other relevant specialty guidance. References are provided so readers and\r\n clinicians can verify key recommendations.\r\n <\/p>\r\n <\/div>\r\n <\/section>\r\n\r\n <\/article>\r\n<\/main>\r\n\r\n<\/body>\r\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Fatty Liver Disease (MASLD): Symptoms, Causes, Ultrasound, Fibrosis & Treatment | UKSONO Healthcare U UKSONO Health Articles Medical Knowledge Centre All Health Articles Explore Liver Health Checks Home \u203a Health Articles \u203a Fatty Liver Disease (MASLD) Liver & Abdominal Health \u00b7 Article 01 Fatty Liver Disease (MASLD) A detailed guide to metabolic dysfunction-associated steatotic liver […]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-6697","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/pages\/6697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/comments?post=6697"}],"version-history":[{"count":4,"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/pages\/6697\/revisions"}],"predecessor-version":[{"id":6702,"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/pages\/6697\/revisions\/6702"}],"wp:attachment":[{"href":"https:\/\/uksono.com\/home\/wp-json\/wp\/v2\/media?parent=6697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}